Stock ATOS ATOSSA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Atossa Therapeutics, Inc.

Equities

ATOS

US04962H5063

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/06/2024 BST 		5-day change 1st Jan Change
1.05 USD +1.94% Intraday chart for Atossa Therapeutics, Inc. -6.25% +19.32%
06-17 Atossa Therapeutics Set to Join Updated Russell 3000 Index MT
05-28 Atossa Therapeutics, Inc. Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Atossa Set to Join Russell 3000 Index Effective June 28, 2024
AQ
Atossa Therapeutics Set to Join Updated Russell 3000 Index
MT
Atossa Set to Join Russell 3000® Index Effective June 28, 2024
AQ
Atossa to Present at the Sidoti Small-Cap Investor Conference
AQ
Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model
AQ
Atossa Therapeutics, Inc. Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model
CI
Atossa Therapeutics Doses Last Patient in Phase 2 Karisma-Endoxifen Trial
MT
Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial
AQ
Atossa Therapeutics, Inc. Announces Last Patient, Last Dose in Its Phase 2 Karisma-Endoxifen Clinical Trial
CI
Atossa Therapeutics Files $100 Million Mixed-Shelf Offering
MT
Tranche Update on Atossa Therapeutics, Inc.'s Equity Buyback Plan announced on June 27, 2023.
CI
Atossa Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
AQ
Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines
AQ
Atossa Therapeutics, Inc. Announces Support of New Breast Cancer Screening Guidelines by U.S. Preventive Services Task Force
CI
Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen
AQ
Atossa Therapeutics, Inc. Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates and (Z)-Endoxifen
CI
Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib in Women with ER+/HER2- Breast Cancer
AQ
Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer
AQ
Atossa Therapeutics and Quantum Leap Healthcare Collaborative Announces I-SPY 2 Clinical Trial to Evaluate (Z-Endoxifen in Combination with Abemaciclib (VERZENIO®?) in Women with ER+/HER2- Breast Cancer
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ATOS Stock
  4. News Atossa Therapeutics, Inc.